DUBAI, 26th November, 2024 (WAM) -- The Interstitial Lung Disease (ILD) Summit, hosted by Boehringer Ingelheim, brought together more than 140 healthcare professionals from the Middle East and Africa to showcase the latest scientific developments in the treatment and management of respiratory conditions such as Idiopathic Pulmonary Fibrosis (IPF), Progressive Fibrosing Interstitial Lung Disease (PF-ILD) and Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD).
The fourth edition of the ILD Summit, accredited by the American Association of Continuing Medical Education (ACCME) and the British Academy of Continuous Medical Education (BACME), took place on 22 and 23 November in Conrad, Dubai, UAE.
Ousama AlHaj, General Manager and Head of Human Pharma for UAE and Near East region, Boehringer Ingelheim, said, “Early diagnosis and intervention are crucial for improving the prognosis of individuals living with ILDs, and multidisciplinary coordination among healthcare providers is essential. By gathering experts in the field of ILD, we gain valuable insights from various disciplines and learn about their clinical experiences, facilitating the exchange of best practices among healthcare professionals."
The summit aims to provide a platform for driving discussions around the latest scientific guidelines and addressing the challenges associated with the diagnosis, follow-ups, and prognosis of ILDs. Ultimately, this can significantly benefit patients in the region, he added.